Silvia V Conde Selected Research

N- (4- cyanophenyl)- 2- (4- (2,3,6,7- tetrahydro- 2,6- dioxo- 1,3- dipropyl- 1H- purin- 8- yl)- phenoxy)acetamide

1/2020	A 2 Adenosine Receptors Mediate Whole-Body Insulin Sensitivity in a Prediabetes Animal Model: Primary Effects on Skeletal Muscle.
4/2015	Disclosing caffeine action on insulin sensitivity: effects on rat skeletal muscle.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silvia V Conde Research Topics

Disease

9	Insulin Resistance 01/2022 - 01/2012
8	Hypoxia (Hypoxemia) 05/2022 - 11/2006
5	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2018
4	Metabolic Diseases (Metabolic Disease) 12/2020 - 01/2018
3	Weight Gain 07/2021 - 01/2012
3	Prediabetic State (Prediabetes) 01/2021 - 01/2020
3	Inflammation (Inflammations) 12/2020 - 08/2020
2	Hypercapnia 05/2022 - 10/2019
2	Obstructive Sleep Apnea 01/2022 - 01/2017
2	Ganglion Cysts (Ganglion) 10/2019 - 12/2012
2	Hypertension (High Blood Pressure) 01/2017 - 01/2012
1	Cognitive Dysfunction 05/2022
1	Alzheimer Disease (Alzheimer's Disease) 05/2022
1	Shock 12/2020
1	Necrosis 12/2020
1	Glucose Intolerance 08/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018
1	Obesity 01/2018
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2017
1	Hypersensitivity (Allergy) 01/2017
1	Hyperventilation 12/2012
1	Acidosis 11/2006

Drug/Important Bio-Agent (IBA)

7	Insulin (Novolin)FDA Link 07/2021 - 01/2012
6	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2018
6	Caffeine (No Doz)FDA LinkGeneric 01/2020 - 01/2012
6	Adenosine (Adenocard)FDA LinkGeneric 10/2019 - 12/2008
4	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2020 - 12/2012
3	LipidsIBA 01/2022 - 05/2019
3	Sucrose (Saccharose)IBA 01/2021 - 01/2012
3	CatecholaminesIBA 01/2020 - 11/2006
3	Neurotransmitter Agents (Neurotransmitter)IBA 10/2019 - 11/2006
2	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA 01/2020 - 04/2015
2	N- (4- cyanophenyl)- 2- (4- (2,3,6,7- tetrahydro- 2,6- dioxo- 1,3- dipropyl- 1H- purin- 8- yl)- phenoxy)acetamideIBA 01/2020 - 04/2015
2	1,3-dipropyl-8-cyclopentylxanthineIBA 01/2020 - 04/2015
2	Purinergic P2 Receptors (ADP Receptor)IBA 10/2019 - 01/2017
2	Dopamine (Intropin)FDA LinkGeneric 12/2012 - 01/2012
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 05/2022
1	Rivastigmine (Exelon)FDA LinkGeneric 05/2022
1	AcetylcholinesteraseIBA 05/2022
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2022
1	Memantine (Namenda)FDA Link 05/2022
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	Bromocriptine (Parlodel)FDA LinkGeneric 01/2021
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 12/2020
1	GlucocorticoidsIBA 12/2020
1	Mifepristone (RU 486)FDA Link 12/2020
1	CorticosteroneIBA 12/2020
1	LipopolysaccharidesIBA 12/2020
1	CarbohydratesIBA 08/2020
1	Biomarkers (Surrogate Marker)IBA 06/2020
1	Blood Glucose (Blood Sugar)IBA 06/2020
1	Drinking WaterIBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 10/2019
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 10/2019
1	NestinIBA 10/2019
1	C-PeptideIBA 05/2019
1	salicylhydroxamic acid (SHAM)IBA 01/2018
1	LeptinIBA 01/2018
1	PurinesIBA 01/2017
1	Purinergic P1 Receptor AntagonistsIBA 01/2017
1	SodiumIBA 04/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2015
1	XanthineIBA 04/2015
1	AminesIBA 04/2015
1	Oxygen (Dioxygen)IBA 12/2012
1	Glutathione (Reduced Glutathione)IBA 01/2012
1	Carvedilol (Coreg)FDA LinkGeneric 01/2012
1	Nonesterified Fatty Acids (NEFA)IBA 01/2012
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2012
1	Dopamine Agonists (Dopamine Agonist)IBA 12/2008

Therapy/Procedure

3	Therapeutics 12/2020 - 01/2018
2	Denervation 01/2021 - 10/2019
1	Hyperbaric Oxygenation 08/2020